Alendronate (Fosamax®)

Common name: Alendronate
Brand name: Fosamax®


What is Alendronate?

Alendronate belongs to the bisphosphonate class of drugs that is used to treat osteoporosis (bone thinning). It works by increasing bone density to reduce breakage.
 

How is Alendronate administered?

Alendronate is administered orally as a tablet.
 

What are possible side effects of this treatment?

Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are some side effects experienced by those who received alendronate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Abdominal pain
  • Bloating
  • Constipation
  • Diarrhea
  • Headache
  • Nausea
  • Pain in bones / joints
 

Is alendronate covered in my province or territory?

Alendronate is covered by all provincial/territorial drug programs.
 

Last Reviewed: July 2017

Plaid for Dad


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Honouring dad this Father’s Day the Canadian way: In plaid

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer.
More

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.
More

Landmark study links tumour evolution to prostate cancer severity

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved.
More


Click here for news archive